APA

Kratochwil C., Giesel F. L., Bruchertseifer F., Mier W., Apostolidis C., Boll R., Murphy K., Haberkorn U. & Morgenstern A. (20150616). ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. : European journal of nuclear medicine and molecular imaging.

Chicago

Kratochwil C, Giesel F L, Bruchertseifer F, Mier W, Apostolidis C, Boll R, Murphy K, Haberkorn U and Morgenstern A. 20150616. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. : European journal of nuclear medicine and molecular imaging.

Harvard

Kratochwil C., Giesel F. L., Bruchertseifer F., Mier W., Apostolidis C., Boll R., Murphy K., Haberkorn U. and Morgenstern A. (20150616). ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. : European journal of nuclear medicine and molecular imaging.

MLA

Kratochwil C, Giesel F L, Bruchertseifer F, Mier W, Apostolidis C, Boll R, Murphy K, Haberkorn U and Morgenstern A. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. : European journal of nuclear medicine and molecular imaging. 20150616.